Althea Technologies, Inc. has acquired the assets and portfolio of Altus Pharmaceuticals. Altus’ portfolio includes its Cross Linked Enzyme Crystal (CLEC) and controlled release injectable technologies for applications ranging from therapeutics to protein purification and catalysis. The controlled release injectable technology involves protein crystallization and complexation using customized manufacturing equipment installed at Althea. Additional assets include a portfolio of product can...